Non-Hodgkin Lymphoma Committee (NHL)
Lymphomas represent the third most common cancer in children and adolescents. The non-Hodgkin's lymphomas comprise a heterogeneous group of tumors, with distinct clinical and pathologic and molecular features. Although intensive multi-agent chemotherapy has made non-Hodgkin's lymphoma one of the most curable malignancies in children and young adults, there is still room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy.
Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin's lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor. Optimal treatment for this group remains a challenge.
The I-BFM NHL Committee and Study Group is the platform to discuss, initiate and perform multinational clinical trials in childhood NHL.
Primary objective of the committee is to improve the outcome and quality of life for children and adolescents with NHL via joined effort of the I-BFM NHL group.
Ways to do so:
- To focus on risk stratification in each NHL disease subset
- To optimize the use of chemotherapy
- To decrease the treatment related mortality
- To follow new trends in Biologic Targeted Therapies
- To support clinical and biological research
Chair:
| Andishe Attarbaschi since 2014, 1st term |
Clinical Trials
-
I-BFM NHL LL 2009 (ongoing)
Study Chair: Jaroslav Sterba, Brno
-
B-NHL BFM 04 (ongoing)
Study Chair: A. Reiter, Gießen
-
B-NHL BFM Rituximab (ongoing)
Study Chair: A. Reiter, Gießen -
I-BFM rare pediatric NHL data registry
Study Chair: Jaroslav Sterba, Zdenka Krenova, Brno
Therapy optimization studies in collaboration with EICNHL:
-
ALCL-Relapse (ongoing)
Study Chair: A. Reiter, Gießen -
ALCL 99 (analyzed)
Study Chair: A. Reiter, Gießen -
EURO-LB02 (completed, analyzed)
Study Chair: A. Reiter, Gießen -
Other Activities
- Development of treatment protocol for children with Nijmegen-Breakage Syndrom and Ataxia teleangiectatica
Meetings
- Non Hodkin`s Lymphoma Committee session at the I-BFM SG Meeting, October 2nd – 4th 2010 in Antalya
Links
I-BFM Rare and cutaneous pediatric non – Hodgkin lymphoma registry
Publications
Meinhardt A*, Burkhardt B*, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A; Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol.
Pillon M, Piglione M, Garaventa A et al: Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer.
van Besien K, Carreras J, Bierman PJ et al: Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant.
D'Angelo V, Crisci S, Casale F: High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. J Exp Clin Cancer Res.
Damm-Welk C, Klapper W, Oschlies I et al: Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol.
Burkhardt B, Reiter A, Landmann E et al: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009 Jul
Meier C, Hoeller S, Bourgau C et al: Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol.
Michos A, Dessypris N, Pourtsidis A etal: Delayed exposure to infections and childhood lymphomas: a case-control study. Cancer Causes Control. 2009
Brugières L, Le Deley MC, Rosolen A et al: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009 Feb
Poirel HA, Cairo MS, Heerema NA et al: Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia.
Dembowska-Baginska B, Perek D, Brozyna A et al: Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). Pediatr Blood Cancer.